Fredag 9 Maj | 19:10:05 Europe / Stockholm

Svenska | English

Pliant Therapeutics, Inc.

Filter

År

Typ

Språk

Rensa

2025-05-01 22:05:00 Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations 1,62 USD | +1,89%

2025-04-07 22:05:00 Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference 1,25 USD | -6,72%

2025-03-17 13:00:00 Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

2025-03-13 12:20:00 Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

2025-03-03 15:27:03 Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis 1,38 USD | -59,88%

2025-02-07 22:58:09 Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis 7,79 USD | -34,81%

2025-01-22 22:00:00 Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 10,92 USD | -1,36%

2025-01-22 14:00:00 Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer 10,92 USD | -1,36%

2024-11-19 00:00:00 Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024 12,79 USD | +3,81%

2024-10-01 22:35:00 Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs 10,55 USD | -5,89%

2024-09-30 22:45:00 Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 11,21 USD | -0,88%

2024-08-28 14:00:00 Pliant Therapeutics to Participate in Upcoming Investor Events 12,88 USD | -1,75%

2024-08-26 15:10:07 Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024 13,45 USD | 0,00%

2024-08-07 22:05:00 Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results 12,54 USD | -4,35%

2024-08-06 22:03:00 Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference 13,11 USD | +1,47%

2024-06-13 22:05:00 Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors 11,97 USD | +1,79%

2024-06-12 22:05:00 Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) 11,76 USD | +4,16%

2024-06-06 14:00:00 Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™ 11,54 USD | -4,63%

2024-05-22 00:50:00 Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference 14,18 USD | -2,81%

2024-05-14 13:30:00 Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis 14,14 USD | +3,44%

2024-05-01 14:00:00 Pliant Therapeutics to Participate in Upcoming Investor Events 12,66 USD | +7,11%

2024-03-27 15:23:38 Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference 14,55 USD | +2,90%

2024-03-12 12:30:00 Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis 15,14 USD | +4,20%

2024-02-27 22:03:00 Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results 17,21 USD | +3,61%

2024-02-04 21:29:07 Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

2024-01-03 14:00:00 Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference 18,06 USD | +0,56%

2023-11-13 22:30:00 Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis 12,85 USD | -7,09%

2023-10-31 21:03:07 Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer 14,67 USD | +5,16%

2023-10-19 14:00:00 Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023 13,88 USD | +2,44%

2023-10-16 22:05:00 Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer 15,40 USD | +0,98%

2023-09-25 22:05:00 Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis 14,58 USD | -2,86%

2023-08-30 14:00:00 Pliant Therapeutics to Participate in Upcoming Investor Conferences 16,71 USD | +0,72%

2023-08-28 22:05:00 Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023 16,55 USD | +1,78%

2023-08-09 22:03:00 Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results 18,18 USD | +0,06%

2023-08-09 14:00:00 Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis 18,18 USD | +0,06%

2023-07-25 14:00:00 Pliant Therapeutics to Participate in Upcoming Investor Conferences 17,65 USD | -0,68%

2023-06-23 13:30:00 Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™ 20,84 USD | -2,07%

2023-05-24 14:00:00 Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference 21,60 USD | +0,70%

2023-05-10 14:05:00 Pliant Therapeutics to Participate in Upcoming Investor Events 23,03 USD | +2,31%

2023-05-09 22:02:00 Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results 22,51 USD | +1,86%

2023-04-30 20:10:28 Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

2023-04-12 14:01:00 Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference 25,40 USD | -3,68%

2023-03-27 14:01:00 Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference 26,33 USD | +2,85%

2023-03-13 13:01:00 Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis 28,20 USD | +0,79%

2023-03-09 22:05:00 Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results 28,57 USD | -9,01%

2023-03-08 22:01:00 Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors 31,40 USD | +1,78%

2023-03-01 14:01:00 Pliant Therapeutics to Participate in Upcoming Investor Events 31,43 USD | -1,35%

2023-02-07 14:01:00 Pliant Therapeutics to Participate in Upcoming Investor Events 32,28 USD | -1,01%

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Pliant Therapeutics, Inc.

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden